EU FUNDING OPPORTUNITIES AND PROJECT MANAGEMENT TIPS

This IMI2 JU topic is designed to generate an information set to help evolve clinical hypothesis generation that will drive the development of new therapeutic interventions for cancer and to identify patient sub-populations that may respond to specific interventions, in particular to immunotherapy. The proposed topic, for the first time, will assemble a consortium to generate a data set sufficient to gain a meaningful view of the tumour micro-environment. The generation of such a data set is the core activity of this IMI2 JU topic while the future purposes (improvement of the currently available treatments and development of potential therapeutic strategies) go beyond the frame of this topic. 

Deadline: 28/12/18

The overall objective of this topic is to determine whether diabetic cardiomyopathy is unique and distinct from the other forms of heart failure such as HFpEF or HCM by performing unbiased statistical clustering analysis from a dense phenotyping of these patient populations. Similar methodology has recently been used to identify phenotypically distinct and more homogeneous HFpEF segments. This approach would facilitate a molecular taxonomy of diabetic cardiomyopathy which is widely accepted in the scientific community and could be applied in the clinics for differentiation from other forms of heart muscle disorders already at disease onset, thereby enabling an optimised and individualised treatment of patients.
Furthermore, a better comprehension of the underlying mechanisms and clinical manifestations of diabetic cardiomyopathy will also allow the development of more translatable and predictable preclinical models to support target and drug discovery.

Deadline:28/02/2018